{
    "clinical_study": {
        "@rank": "70637", 
        "arm_group": [
            {
                "arm_group_label": "AZD1775+carboplatin and pemetrexed drug", 
                "arm_group_type": "Experimental", 
                "description": "Randomized - AZD1775 + carboplatin +pemetrexed Maintenance - AZD1775 + pemetrexed until disease progression or toxicity"
            }, 
            {
                "arm_group_label": "Placebo+carboplatin + pemetrexed", 
                "arm_group_type": "Experimental", 
                "description": "Randomized - Matching Placebo to AZD 1775 + carboplatin + pemetrexed, Maximum 4 Cycles Maintenance - AZD1775 + pemtrexed or  Matching Placebo AZD1775 + pemetrexed until disease progression or unacceptable toxicity"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to combine AZD1775 with standard front-line chemotherapy in\n      subjects with advanced NSCLC."
        }, 
        "brief_title": "Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomised, double-blind, placebo-controlled, phase II trial comparing AZD1775\n      plus carboplatin and pemetrexed with a maintenance phase."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Provision of informed consent prior to any study specific procedures\n\n          -  Histologic or cytologic diagnosis of advanced NSCLC, Recurrent or Stage IV disease\n             (according to American Joint Committee on Cancer (AJCC) staging system, v7.0).\n\n          -  No prior chemotherapy for locally advanced or metastatic disease\n\n          -  Subjects with a known EGFR mutation must have received previous treatment with an\n             EGFR tyrosine kinase inhibitor; and subjects with a known ALK translocation must have\n             received previous treatment with an ALK inhibitor.\n\n          -  No prior radiation therapy to the whole pelvis or to \u226525% of the total bone marrow\n             area.\n\n          -  At least one measurable lesion according to Response Evaluation Criteria in Solid\n             Tumours (RECIST) v1.1\n\n          -  Mandatory availability of tumour tissue (archival or fresh if archival is not\n             available) for TP53 determination.\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.\n\n          -  Absolute neutrophil count (ANC) \u22651500/\u03bcL\n\n          -  Hemoglobin (Hgb) \u226510 g/dL\n\n          -  Platelets \u2265100,000/\u03bcL\n\n          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST), \u22643.0 x the upper\n             limit of normal (ULN); 5 x ULN if known hepatic metastases\n\n          -  Total bilirubin \u22641.5 x ULN, unless secondary to Gilbert's disease\n\n          -  Serum creatinine \u22641.5 x ULN and a calculate creatinine clearance (CrCl) \u226545 mL/min by\n             the Cockcroft-Gault method\n\n          -  Ability to swallow oral medication\n\n          -  Fertile male subjects willing to use at least one medically acceptable form of birth\n             control for the duration of the study and for 2 weeks after treatment stops\n\n          -  Female subjects who are not of childbearing potential and fertile female subjects of\n             childbearing potential who agree to use adequate contraceptive measures who are not\n             breastfeeding, and who have a negative serum or urine pregnancy test within 72 hours\n             prior to start of study treatment\n\n          -  Predicted life expectancy \u226512 weeks\n\n          -  Must be \u226518 years of age\n\n          -  Willingness and ability to comply with study and follow-up procedures\n\n          -  Ability to understand the nature of this trial and give written informed consent\n             Exclusion criteria\n\n          -  Use of a study drug \u226421 days or 5 half-lives (whichever is shorter) prior to the\n             first dose of AZD1775\n\n          -  Major surgical procedures \u226428 days of beginning AZD1775, or minor surgical procedures\n             \u22647 days\n\n          -  Known central nervous system (CNS) disease\n\n          -  Subject has had prescription or non-prescription drugs or other products (i.e.\n             grapefruit juice) known to be sensitive CYP3A4 substrates\n\n          -  Any known hypersensitivity or contraindication to the components of study treatment\n\n          -  Any of the following cardiac diseases currently or within the last 6 months as\n             defined by New York Heart Association ([NYHA] Appendix G) \u2265 Class 2\n\n          -  Corrected QT interval (QTc) >470 msec (as calculated by Fridericia correction\n             formula) at study entry or congenital long QT syndrome.\n\n          -  Pregnant or lactating\n\n          -  Any serious, active underlying medical condition that would impair the ability of the\n             subjects to receive study treatment\n\n          -  Unable or unwilling to take folic acid or vitamin B12\n\n          -  Presence of other active cancers, or history of treatment for invasive cancer \u22643\n             years\n\n          -  Psychological, familial, sociological, or geographical conditions that do not permit\n             compliance with the protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02087241", 
            "org_study_id": "D6011C00002"
        }, 
        "intervention": [
            {
                "arm_group_label": "AZD1775+carboplatin and pemetrexed drug", 
                "description": "AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies", 
                "intervention_name": "AZD1775", 
                "intervention_type": "Drug", 
                "other_name": "MK-1775"
            }, 
            {
                "arm_group_label": "Placebo+carboplatin + pemetrexed", 
                "description": "AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies", 
                "intervention_name": "AZD1775 Matching Placebo", 
                "intervention_type": "Drug", 
                "other_name": "MK1775"
            }, 
            {
                "arm_group_label": [
                    "AZD1775+carboplatin and pemetrexed drug", 
                    "Placebo+carboplatin + pemetrexed"
                ], 
                "description": "This drug is a part of a general group of chemotherapy drugs called anti-metabolites. It prevents cells from using folate to make DNA and RNA. Because cancer cells need these substances to make new cells, this drug helps to stop the growth of cancer cells.", 
                "intervention_name": "pemetrexed", 
                "intervention_type": "Drug", 
                "other_name": "MK1775"
            }, 
            {
                "arm_group_label": [
                    "AZD1775+carboplatin and pemetrexed drug", 
                    "Placebo+carboplatin + pemetrexed"
                ], 
                "description": "This drug is a platinum chemotherapy drug that acts like an alkylating agent. It stops the growth of cancer cells, causing the cells to die.", 
                "intervention_name": "carboplatin", 
                "intervention_type": "Drug", 
                "other_name": "MK1775"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pemetrexed", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Stage IV Lung Cancer", 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double-Blind Randomised Phase II Trial of Carboplatin and Pemetrexed With or Without AZD1775 in Patients With Previously Untreated Stage IV Non-Squamous Non-Small-Cell Lung Cancer", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Bernadette M Weidman", 
            "phone": "302-897-5559"
        }, 
        "overall_contact_backup": {
            "email": "joanne.meredith@astrazeneca.com", 
            "last_name": "Joanne Meredith", 
            "phone": "(813) 920-7423"
        }, 
        "overall_official": {
            "affiliation": "SCRI Development Innovations, LLC", 
            "last_name": "David R Spigel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Progression free survival is defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the subject withdraws from randomised therapy or receives another anti-cancer therapy prior to progression.", 
                "measure": "Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Progression free survival is defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the subject withdraws from randomised therapy or receives another anti-cancer therapy prior to progression.", 
                "measure": "Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02087241"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The objective response rate is defined as the number of the subjects with a confirmed best overall response of CR or PR divided by the number of subjects in the Full Analysis Set (FAS) for whom measureable disease is present at baseline", 
                "measure": "Assess the objective response rates in each arm", 
                "safety_issue": "No", 
                "time_frame": "Up to a maximum of 4 treatment cycles (treatment cycles will be repeated every 21 days)"
            }, 
            {
                "description": "the disease control rate is defined as the percentage of FAS subjects with a best overall response of CR, PR or SD).", 
                "measure": "Assess the disease control rate in each treatment arm", 
                "safety_issue": "No", 
                "time_frame": "Up to a maximum of 4 treatment cycles (treatment cycles will be repeated every 21 days)"
            }, 
            {
                "description": "Duration of response is defined as the time from the date of first documented response until the date of documented progression or any cause death.", 
                "measure": "Assess the duration of response in each treatment arm", 
                "safety_issue": "No", 
                "time_frame": "Up to a maximum of 4 treatment cycles (treatment cycles will be repeated every 21 days)"
            }, 
            {
                "description": "Safety profiles will be assessed in terms of AEs and laboratory data, vital signs, and ECG data that will be collected for all subjects.", 
                "measure": "Evaluate safety in each treatment arm", 
                "safety_issue": "Yes", 
                "time_frame": "Up to disease progression or unacceptable toxicity (there is no time limit on the length of treatment"
            }, 
            {
                "description": "Overall survival is defined as the time from the date of randomization until death due to any cause.", 
                "measure": "Assess overall survival in each treatment arm", 
                "safety_issue": "No", 
                "time_frame": "Up to a maximum of 4 treatment cycles (treatment cycles will be repeated every 21 days)"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}